The cutting edge of bone
Advancing monoclonal antibodies, multi-specifics and ADCs engineered to have enhanced efficacy in the skeleton
Capabilities
Platform capabilities
Bone is not just inert scaffold - it is an active driver of many disease states. We have built a first-in-class antibody engineering platform to enhance the performance of antibodies in bone.
1
Disease, target and modality identification
Tailored engineering approaches optimized for solid tumors, liquid tumors, osteoporosis, arthritis, and rare skeletal dysplasias across monoclonal antibodies, multi-specifics, or antibody-drug conjugates.
2
Antibody re-engineering
Apply proprietary datasets, AI/ML approaches and proprietary experimental systems to enhance bone performance while also achieving excellent developability.
3
Selectively enhanced efficacy in the skeleton
Production of a bone enhanced drug with exceptional developability and safety.
